ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment"

  • Abstract Number: 1298 • 2012 ACR/ARHP Annual Meeting

    Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach

    Shunichi Kumagai1, Yoshiaki Hagiwara2, Yoshihide Ichise1, Sho Sendo3, Nobuhiko Okada1, Jun Saegusa4 and Goh Tsuji5, 1Center of rheumatic diseases, Shinko hospital, Kobe, Japan, 2Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, 3Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, 4Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 5Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan

    Background/Purpose: Salazosulfapyridine (SASP) is acetylated in liver by N-acetyltransferase2 (NAT2) in the track of metabolism. Previous studies have shown that genotyping of NAT2 is adequate…
  • Abstract Number: 773 • 2012 ACR/ARHP Annual Meeting

    Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria

    Josef S. Smolen1, D. Aletaha2, D. Gruben3, J. D. Bradley4, S. H. Zwillich3, S. Krishnaswami3, B. Benda5 and C. Mebus6, 1Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna, Vienna, Austria, 2Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Pfizer Inc., Groton, CT, 4Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, 5Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, 6Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This analysis evaluated the rates…
  • Abstract Number: 369 • 2012 ACR/ARHP Annual Meeting

    Differences in Short-Term Radiographic Progression Following Early Response to Adalimumab Plus Methotrexate Vs. Methotrexate Alone

    Ronald F. van Vollenhoven1, James W. Shaw2, Mary A. Cifaldi3, James Signorovitch4, Eric Q. Wu4, Thomas Samuelson4, Elizabeth Faust4 and Paul Emery5, 1Karolinska Institute, Stockholm, Sweden, 2Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, 3Abbott Laboratories, Abbott Park, IL, 4Analysis Group, Inc., Boston, MA, 5Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom

    Background/Purpose: To prevent disease progression, treat-to-target recommendations for rheumatoid arthritis (RA) include the evaluation and adjustment of drug therapy at least every 3 months until…
  • Abstract Number: 1846 • 2012 ACR/ARHP Annual Meeting

    Observation of Persistence Rates and Potential Costs Savings Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis in England, Wales and Northen Ireland Clinical Practice

    Mike Russell1, Jen Timoshanko1, Graeme Duncan2, Angela Spandley1 and Samantha Roskell3, 1UCB Pharma, Slough, United Kingdom, 2Healthcare at Home Ltd, Burton on Trent, United Kingdom, 3Rheumatology, Cannock Chase Hospital, Cannock, United Kingdom

    Background/Purpose: Rheumatoid arthritis (RA) therapy in the UK is standardized by the National Institute for Health and Clinical Excellence (NICE).  To be eligible for anti-TNF…
  • Abstract Number: 1312 • 2012 ACR/ARHP Annual Meeting

    Clinical Response At 12 Weeks Predicts Long-Term Remission and the Extent of Radiographic Progression in Japanese Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol with and without Methotrexate Coadministration

    Tsutomu Takeuchi1, Kazuhiko Yamamoto2, Hisashi Yamanaka3, Naoki Ishiguro4, Yoshiya Tanaka5, Katsumi Eguchi6, Akira Watanabe7, Hideki Origasa8, Toshiharu Shoji9, Nobuyuki Miyasaka10 and Takao Koike11, 1Keio University School of Medicine, Tokyo, Japan, 2Department of Allergy & Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 4Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, 5The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6Sasebo City General Hospital, Sasebo, Nagasaki, Japan, 7Research Division for Development of Anti-Infectious Agents, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan, 8Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, 9Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, 10Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, 11Sapporo medical center NTT EC, Sapporo, Japan

    Background/Purpose: The majority of patients (pts) with active rheumatoid arthritis (RA) have previously been shown to respond during the first 12 weeks (wks)  of certolizumab…
  • Abstract Number: 774 • 2012 ACR/ARHP Annual Meeting

    A CD4+ T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis

    Arthur G. Pratt1, Philip M. Brown2, Simon J. Cockell3, Gillian Wilson4 and John D. Isaacs1, 1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 2Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom, 3Bioinformatics Unit, Newcastle University, Newcastle-upon-Tyne, United Kingdom, 4Directorate of Musculoskeletal Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom

    Background/Purpose: The mechanism of action of methotrexate (MTX) in the management of rheumatoid arthritis (RA) remains incompletely understood. It is nonetheless capable of inducing clinical…
  • Abstract Number: 331 • 2012 ACR/ARHP Annual Meeting

    PDL241, a Novel Humanized Monoclonal Antibody, Reveals CD319 As a Therapeutic Target for Rheumatoid Arthritis

    Michel P.M. Vierboom1, Jacky Woo2, Hakju Kwon2, Debra Chao2, Shiming Ye2, Jianmin Li2, Karen Lin2, Irene Tang2, Nicole Belmar2, Taymar Hartman2, Elia Breedveld1, Bert A. ‘t Hart1 and Gary C. Starling2, 1Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, 2Abbott Biotherapeutics, Redwood City, CA

    Background/Purpose: Current therapies have shown tremendous progress in the treatment of rheumatoïd arthritis (RA). However, a substantial group of RA patients are still refractory to…
  • Abstract Number: 1829 • 2012 ACR/ARHP Annual Meeting

    Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance

    Machaon Bonafede1, Crystal Watson2, George Joseph2, Nicole Princic1 and David J. Harrison2, 1Thomson Reuters Healthcare, Cambridge, MA, 2Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Tumor Necrosis Factor Inhibitors (TNFi) are the mainstay of treatment for rheumatoid arthritis (RA) in patients with moderate to severe disease. The three most…
  • Abstract Number: 1279 • 2012 ACR/ARHP Annual Meeting

    First in Human Study with Recombinant Anti-IL-21 Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis

    Stanislav Ignatenko1, Birte K. Skrumsager2, Adam Steensberg3 and Ulrik Mouritzen3, 1Charité Research Organization GmbH, Berlin, Germany, 2Clinical Pharmacology Biopharm, Novo Nordisk A/S, Copenhagen, Denmark, 3Medical & Science, Inflammation, Novo Nordisk A/S, Copenhagen, Denmark

    Background/Purpose: Interleukin-21 (IL-21), a cytokine produced by activated T cells (especially T17 and TFH cells), has a proinflammatory and pleiotropic nature, and drives mainly activation…
  • Abstract Number: 776 • 2012 ACR/ARHP Annual Meeting

    A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission

    Katerina Chatzidionysiou1, Carl Turesson2, Annika Teleman3, Ann Knight4, Elisabet Lindqvist5, Per Larsson6, Lars Cöster7, Barbro Rydberg8, Ronald F. van Vollenhoven9 and Mikael Heimbürger10, 1Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, 2Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 3Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, 4Dept of Rheumatology, Institution for Medical Sciences, Uppsala University, Uppsala, Sweden, 5Department of Clinical Sciences, Section for Rheumatology Lund University, Lund, Sweden, 6Dept of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, 7Department of Rheumatology, University Hospital, Linköping, Sweden, 8Department of Rheumatology, Kärnsjukhuset, Skövde, Sweden, 9Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, 10Medical department, Abbott Scandinavia, Stockholm, Sweden

    Background/Purpose: Treatment with TNF blockers, once started as therapy for RA, is usually continued indefinitely. Information about the possibility to discontinue anti-TNF therapy in RA…
  • Abstract Number: 336 • 2012 ACR/ARHP Annual Meeting

    Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody® For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile

    Maarten Van Roy1, Hans Ulrichts2, Stefaan Rossenu2, Sandy Jacobs2, Sofie Poelmans3, Gert Verheyden2, Michel Vierboom4, Bert 't Hart4, Judith Baumeister1 and Josefin-Beate Holz5, 1Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, 2Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, 3Pharmacology, Ablynx NV, Gent, Belgium, 4Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, 5Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium

    Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor IL-6R. IL-6 plays an important role in the…
  • Abstract Number: 1831 • 2012 ACR/ARHP Annual Meeting

    Evaluation of the Cost-Effectiveness of Rheumatoid Arthritis Treatment with Biologic Agents Using the IORRA Cohort Database

    Eiichi Tanaka1, Eisuke Inoue2, Daisuke Hoshi3, Akiko Kobayashi2, Naoki Sugimoto2, Kumi Shidara2, Eri Sato3, Yasushi Inoue3, Yohei Seto2, Ayako Nakajima4, Shigeki Momohara3, Atsuo Taniguchi2 and Hisashi Yamanaka3, 1Tokyo Women's Medical University, Tokyo, Japan, 2Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 4Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA), a chronic inflammatory disorder, causes a significant decrease in quality of life. Recently developed biologic agents (BAs) have caused a considerable…
  • Abstract Number: 1283 • 2012 ACR/ARHP Annual Meeting

    Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies

    Gerd Burmester1, Désirée van der Heijde2, Vibeke Strand3, Cristiano A. F. Zerbini4, Carol A. Connell5, Charles A. Mebus5, Samuel H. Zwillich6, John D. Bradley5, David Gruben5 and Gene Wallenstein5, 1Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, 4Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, 5Pfizer Inc., Groton, CT, 6Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. The efficacy and safety of…
  • Abstract Number: 771 • 2012 ACR/ARHP Annual Meeting

    Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results

    Yoshiya Tanaka1, Shintaro Hirata1, Shunsuke Fukuyo1, Masao Nawata2, Satoshi Kubo2, Kunihiro Yamaoka2 and Kazuyoshi Saito1, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

    Background/Purpose: Discontinuing anti-TNF therapy after achieving a stable low disease activity (LDA) or remission (REM) state in rheumatoid arthritis (RA) has become an important area…
  • Abstract Number: 349 • 2012 ACR/ARHP Annual Meeting

    Preliminary Results From a Controlled Study Assessing the Humoral Immune Response to Vaccines in Rheumatoid Arthritis Patients Treated with Tocilizumab

    Clifton O. Bingham III1, Warren C. Rizzo2, Micki Klearman3, Azra Hassanali4, Ruchi Upmanyu5 and Alan J. Kivitz6, 1Rheumatology, Johns Hopkins University, Baltimore, MD, 2Advanced Arthritis Care & Research, Scottsdale, AZ, 3Genentech Inc, South San Francisco, CA, 4Genentech Inc, San Francisco, CA, 5Roche, Welwyn Garden City, United Kingdom, 6Altoona Center for Clinical Research, Duncansville, PA

    Background/Purpose: Tocilizumab (TCZ) is an IL-6–receptor inhibitor for treatment of rheumatoid arthritis (RA) patients (pts). Because TCZ may impact how IL-6 modulates T-cell activation and…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology